Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin].

Muto M, Nishio S, Takemoto S, Ota S, Sonoda G, Ushijima K, Kamura T.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1419-21. Japanese.

PMID:
24196084
2.

Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.

Watanabe M, Aoki Y, Tomita M, Sato T, Takaki Y, Kato N, Kikuchi M, Kase H, Tanaka K.

Gynecol Oncol. 2002 Feb;84(2):335-8.

PMID:
11812097
3.

Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer.

Yoshida H, Sumi T, Abe K, Ishiko O.

Eur J Gynaecol Oncol. 2009;30(5):583-5.

PMID:
19899423
4.

[A case of ovarian cancer with Parkinson's disease treated by combined chemotherapy with paclitaxel and carboplatin followed by surgery].

Furukawa M, Fujiwara H, Urabe S, Egawa M, Fujitoh N, Sakashita T, Date K, Mizunoe T, Ueda K, Urabe T.

Gan To Kagaku Ryoho. 2003 Dec;30(13):2129-32. Japanese.

PMID:
14712777
6.

[A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy].

Fujiwara K, Maehata K, Kohno I, Yoden E, Imajo Y, Mikami Y.

Gan To Kagaku Ryoho. 2000 Dec;27(14):2259-62. Japanese.

PMID:
11142173
7.

[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].

Furuya Y, Takihana Y, Araki I, Tanabe N, Takeda M.

Gan To Kagaku Ryoho. 2003 Jul;30(7):1017-20. Japanese.

PMID:
12894722
8.

Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).

Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.

Anticancer Res. 2001 Mar-Apr;21(2B):1487-94.

PMID:
11396237
9.

Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study.

Kuzuya K, Ishikawa H, Nakanishi T, Kikkawa F, Nawa A, Fujimura H, Iwase A, Arii Y, Kawai M, Hattori S, Sakakibara K, Sasayama E, Furuhashi Y, Suzuki T, Mizutani S; Tokai Gynecologic Oncology Group..

Int J Clin Oncol. 2001 Dec;6(6):271-8.

PMID:
11828945
10.

Primary peritoneal clear cell carcinoma: excellent results from paclitaxel and carboplatin combination chemotherapy.

Ichimura T, Ishiko O, Nishimura S, Kojima T, Shimura K.

Oncol Rep. 2001 Nov-Dec;8(6):1243-5.

PMID:
11605041
11.

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.

Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K.

Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-17-S2-22.

PMID:
9045330
12.

[A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].

Iwasaki K, Komuro Y, Masumoto N, Asaoka K, Ishitani K.

Gan To Kagaku Ryoho. 1999 Sep;26(10):1483-6. Japanese.

PMID:
10500539
13.

Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report.

Yokoyama Y, Futagami M, Higuchi T, Mizunuma H.

Eur J Gynaecol Oncol. 2006;27(4):437-9.

PMID:
17009648
14.

Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Neven P, Amant F.

Int J Gynecol Cancer. 2012 May;22(4):617-22. doi: 10.1097/IGC.0b013e31824a3385.

PMID:
22426408
15.
16.

Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.

Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-30-S15-35.

PMID:
9346219
17.

Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.

Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C.

Anticancer Res. 2000 Sep-Oct;20(5C):4047-50.

PMID:
11268499
18.

Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.

PMID:
7544025
19.

Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.

Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou CA, Markaki S, Dimopoulos MA.

Eur J Gynaecol Oncol. 2005;26(6):627-31.

PMID:
16398224
20.

Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.

Shechter-Maor G, Bruchim I, Ben-Harim Z, Altaras M, Fishman A.

Int J Gynecol Cancer. 2009 May;19(4):662-4. doi: 10.1111/IGC.0b013e3181a3d626.

PMID:
19509567

Supplemental Content

Support Center